Navigation Links
Uroplasty to Present at the 11th Annual JMP Securities Research Conference
Date:5/7/2012

MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 11th Annual JMP Securities Research Conference at 12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in San Francisco.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/jmp17/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uropla
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Uroplasty to Present at the 24th Annual ROTH Conference
2. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
3. Uroplasty Reports Third Quarter of Fiscal 2012 Financial Results
4. Uroplasty to Issue Third Quarter 2012 Financial Results on January 26, 2012
5. Uroplasty to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference
6. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
7. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
8. Uroplasty to Issue Second Quarter 2012 Financial Results on October 27, 2011
9. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
10. Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
11. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Second Quarter 2015 Investor Conference Call and webcast ... The call will cover an update on Merrimack,s ... 2015 financials. A press release detailing the information to ... afternoon of Monday, August 10. Investors and the general ...
(Date:8/3/2015)... , Aug. 3, 2015  Celsion Corporation ... Company will host a conference call to discuss ... an update on its development programs for ThermoDox®, ... two newly acquired technology platforms, TheraPlas™ and TheraSilence™, ... EDT on Monday, August 10, 2015. To participate ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... BETHLEHEM, Pa., Jan. 3, 2012  Particle Sciences, a leading ... module to its DOSE™ program.  The DOSE™ program ... modeling tools to efficiently arrive at the optimal ... form.  Previously, Particle Sciences implemented software solutions for ...
... Institute ( www.ecri.org ), an independent nonprofit that ... listed 10 health technology issues that hospital leaders ... The just-released list takes into account the convergence ... currently facing healthcare executives. (Photo:  ...
Cached Medicine Technology:Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 3ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 4
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor ... in favor of the firm’s client Rebecca Hamsher, deciding that in accordance with ... reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental health ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... diseases researchers from the University of Pittsburgh School of Medicine are leading a ... prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by the ...
(Date:8/3/2015)... Texas (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision ... and reduce health care costs. , Annually, more than 8.6 million adverse ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
Breaking Medicine News(10 mins):Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... therapy changed as needed, study found , , MONDAY, May ... have only a 50-50 chance that their doctors will ... a new study finds. , Treating high blood pressure ... pressure can lead to increased risk for heart attack, ...
... Medical Center-led pilot study that showed antidepressants can significantly ... cancer patients is the focus of an article published ... the publications produced by the Journal of American Medical ... UNMCs William Lydiatt, M.D., and Bill Burke, M.D., showed ...
... new life as a stroke treatment, researchers say. , ... inhibiting white blood cells and enzymes that, at ... respectively, says Dr. David Hess, chair of the Department ... of Medicine. The broad-spectrum antibiotic also seems to reduce ...
... clinical trial led by a University of North Carolina ... an effective treatment for dysplasia in people with Barretts ... cancer. , The interim results show there is a ... placebo or sham treatment, said Dr. Nicholas Shaheen, principal ...
... International,Meeting, FAIRFAX, Va., May 19 The American ... a cancer,survivor in the Boston area who has dedicated ... the local community. The winner of the Survivor Circle ... on Tuesday, September 23,2008, at the Boston Convention and ...
... NY) Michael Brownlee, M.D., the Anita and Jack ... of Medicine of Yeshiva University, has been selected by ... prestigious David Rumbough Award for Scientific Excellence. The ... to diabetes research. Actress Dina Merrill established this ...
Cached Medicine News:Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 2Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2Health News:Award Honors Boston Cancer Survivor Who Gives Back 2Health News:Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: